Americans for Safe and Effective Medicines (ASEM), a national advocacy organization dedicated to protecting patients from illegal mass compounding, counterfeit products, and misleading marketing, launched a new ad campaign in the Beltway this week to highlight patient safety concerns related to the U.S. Department of Health and Human Services’ (HHS) recent policy on the compounding of certain peptides.
The ads, some of which are included below for reference, will run online across the Washington, D.C. area online and at select physical locations, like Ronald Reagan Washington National Airport (DCA) through November 13, when the public comment period on the HHS policy closes.
The campaign highlights concerns about unapproved peptides and their associated safety risks, ingredients sourced from foreign manufacturers, and the potential dangers of exposing more patients to untested products without adequate oversight.
As ASEM Chief Policy Officer Fred Mills, Jr., PharmD, emphasized:
“Patients should not be guinea pigs for untested peptides. These unapproved products have already reached Americans through questionable online channels. Opening the door to more without adequate safeguards only puts patients at greater risk. HHS needs to put patient safety first.”
The campaign also encourages the public to join ASEM’s sign-on letter to HHS, calling on the Department to reconsider the policy and prioritize patient safety.
About Americans for Safe and Effective Medicines
Americans for Safe and Effective Medicines (ASEM) is a non-partisan 501(c)(4) non-profit organization dedicated to combating illegal mass compounding, counterfeit products, and misleading marketing practices. ASEM advocates for robust Food and Drug Administration enforcement and legislative and regulatory accountability on behalf of patients.
For more information, please visit safeandeffectivemeds.org and follow us on LinkedIn, X, Instagram, Facebook, and TikTok.